These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38740543)

  • 1. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Zheng DY; Wang YN; Huang YH; Jiang M; Ma YN; Dai C
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1745-1759. PubMed ID: 38740543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
    Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study.
    Ramos GP; Dimopoulos C; McDonald NM; Janssens LP; Hung KW; Proctor D; Ruggiero E; Kane S; Bruining DH; Faubion WA; Raffals LE; Loftus EV; Al-Bawardy B
    Inflamm Bowel Dis; 2021 Jul; 27(8):1270-1276. PubMed ID: 33165569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
    Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
    Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
    Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
    Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
    United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
    Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
    Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
    King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
    Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Vedolizumab Treatment and Arthritis/Arthralgia in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Alves Halpern G; Gomes C; Thaytala Quintino Falcon B; Prigol Dalfovo M; De Carvalho Maia J; Brandão Oliveira D
    J Gastrointestin Liver Dis; 2024 Sep; 33(3):379-385. PubMed ID: 39348571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
    Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
    J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
    Vavricka SR; Rogler G; Gantenbein C; Spoerri M; Prinz Vavricka M; Navarini AA; French LE; Safroneeva E; Fournier N; Straumann A; Froehlich F; Fried M; Michetti P; Seibold F; Lakatos PL; Peyrin-Biroulet L; Schoepfer AM
    Inflamm Bowel Dis; 2015 Aug; 21(8):1794-800. PubMed ID: 26020601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.
    Kopylov U; Burisch J; Ben-Horin S; Braegger F; Fernández-Nistal A; Lara N; Heinrich HS; Vavricka SR
    Inflamm Bowel Dis; 2023 Nov; 29(11):1713-1722. PubMed ID: 37158585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin Manifestations of Inflammatory Bowel Disease.
    Greuter T; Navarini A; Vavricka SR
    Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
    Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
    Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
    He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
    Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.